Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2013 Nov 9

PMID 24202327

Citations 21

Authors

Antonino Grassadonia

Pasquale Cioffi

Felice Simiele

Laura Iezzi

Marinella Zilli

Clara Natoli

Affiliations

Soon will be listed here.

Abstract

Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a variety of cytotoxic and molecular targeted agents in many different solid tumors, including breast, prostate, pancreatic, lung and ovarian cancer. Hb-HDACIs have a quite good toxicity profile and are now being tested in phase I and II clinical trials in solid tumors with promising results in selected neoplasms, such as hepatocarcinoma. This review will focus on their clinical activity and safety in patients with advanced solid neoplasms.

Citing Articles

A Review on Molecular Docking on HDAC Isoforms: Novel Tool for Designing Selective Inhibitors.

Drakontaeidi A, Pontiki E Pharmaceuticals (Basel). 2023; 16(12).

PMID: 38139766 PMC: 10746130. DOI: 10.3390/ph16121639.

Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: A report from the Pediatric Brain Tumor Consortium (PBTC-047).

Monje M, Cooney T, Glod J, Huang J, Peer C, Faury D Neuro Oncol. 2023; 25(12):2262-2272.

PMID: 37526549 PMC: 10708931. DOI: 10.1093/neuonc/noad141.

Molecular Research in Pancreatic Cancer: Small Molecule Inhibitors, Their Mechanistic Pathways and Beyond.

Shetu S, James N, Rivera G, Bandyopadhyay D Curr Issues Mol Biol. 2023; 45(3):1914-1949.

PMID: 36975494 PMC: 10047141. DOI: 10.3390/cimb45030124.

Histone deacetylase inhibitor, panobinostat, exerts anti-proliferative effect with partial normalization from aberrant epigenetic states on granulosa cell tumor cell lines.

Hazama Y, Tsujioka T, Kitanaka A, Tohyama K, Shimoya K PLoS One. 2022; 17(7):e0271245.

PMID: 35802681 PMC: 9269920. DOI: 10.1371/journal.pone.0271245.

Interpatient Heterogeneity in Drug Response and Protein Biomarker Expression of Recurrent Ovarian Cancer.

Hoffmann O, Regenauer M, Czogalla B, Brambs C, Burges A, Mayer B Cancers (Basel). 2022; 14(9).

PMID: 35565408 PMC: 9103312. DOI: 10.3390/cancers14092279.

References

van Engeland M, Derks S, Smits K, Meijer G, Herman J . Colorectal cancer epigenetics: complex simplicity. J Clin Oncol. 2011; 29(10):1382-91. DOI: 10.1200/JCO.2010.28.2319. View

Modesitt S, Sill M, Hoffman J, Bender D . A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 2008; 109(2):182-6. DOI: 10.1016/j.ygyno.2008.01.009. View

Marks P, Xu W . Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem. 2009; 107(4):600-8. PMC: 2766855. DOI: 10.1002/jcb.22185. View

Fakih M, Pendyala L, Fetterly G, Toth K, Zwiebel J, Espinoza-Delgado I . A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clin Cancer Res. 2009; 15(9):3189-95. PMC: 4134938. DOI: 10.1158/1078-0432.CCR-08-2999. View

Woyach J, Kloos R, Ringel M, Arbogast D, Collamore M, Zwiebel J . Lack of therapeutic effect of the histone deacetylase inhibitor vorinostat in patients with metastatic radioiodine-refractory thyroid carcinoma. J Clin Endocrinol Metab. 2008; 94(1):164-70. PMC: 2630867. DOI: 10.1210/jc.2008-1631. View

Chen L, Meng S, Wang H, Bali P, Bai W, Li B . Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Mol Cancer Ther. 2005; 4(9):1311-9. DOI: 10.1158/1535-7163.MCT-04-0287. View

Spratlin J, Pitts T, Kulikowski G, Morelli M, Tentler J, Serkova N . Synergistic activity of histone deacetylase and proteasome inhibition against pancreatic and hepatocellular cancer cell lines. Anticancer Res. 2011; 31(4):1093-103. PMC: 3866806. View

Novotny-Diermayr V, Sangthongpitag K, Hu C, Wu X, Sausgruber N, Yeo P . SB939, a novel potent and orally active histone deacetylase inhibitor with high tumor exposure and efficacy in mouse models of colorectal cancer. Mol Cancer Ther. 2010; 9(3):642-52. DOI: 10.1158/1535-7163.MCT-09-0689. View

Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C . Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. J Natl Cancer Inst. 1992; 84(22):1736-40. DOI: 10.1093/jnci/84.22.1736. View

10.

Munster P, Thurn K, Thomas S, Raha P, Lacevic M, Miller A . A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer. Br J Cancer. 2011; 104(12):1828-35. PMC: 3111195. DOI: 10.1038/bjc.2011.156. View

11.

Abbas A, Gupta S . The role of histone deacetylases in prostate cancer. Epigenetics. 2008; 3(6):300-9. PMC: 2683066. DOI: 10.4161/epi.3.6.7273. View

12.

Luu T, Morgan R, Leong L, Lim D, McNamara M, Portnow J . A phase II trial of vorinostat (suberoylanilide hydroxamic acid) in metastatic breast cancer: a California Cancer Consortium study. Clin Cancer Res. 2008; 14(21):7138-42. PMC: 3543872. DOI: 10.1158/1078-0432.CCR-08-0122. View

13.

Strickler J, Starodub A, Jia J, Meadows K, Nixon A, Dellinger A . Phase I study of bevacizumab, everolimus, and panobinostat (LBH-589) in advanced solid tumors. Cancer Chemother Pharmacol. 2012; 70(2):251-8. PMC: 3793400. DOI: 10.1007/s00280-012-1911-1. View

14.

Witter D, Belvedere S, Chen L, Secrist J, Mosley R, Miller T . Benzo[b]thiophene-based histone deacetylase inhibitors. Bioorg Med Chem Lett. 2007; 17(16):4562-7. DOI: 10.1016/j.bmcl.2007.05.091. View

15.

Moffat D, Patel S, Day F, Belfield A, Donald A, Rowlands M . Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrimidine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. J Med Chem. 2010; 53(24):8663-78. DOI: 10.1021/jm101177s. View

16.

Wilson P, El-Khoueiry A, Iqbal S, Fazzone W, LaBonte M, Groshen S . A phase I/II trial of vorinostat in combination with 5-fluorouracil in patients with metastatic colorectal cancer who previously failed 5-FU-based chemotherapy. Cancer Chemother Pharmacol. 2010; 65(5):979-88. DOI: 10.1007/s00280-009-1236-x. View

17.

Kitamura T, Connolly K, Ruffino L, Ajiki T, Lueckgen A, DiGiovanni J . The therapeutic effect of histone deacetylase inhibitor PCI-24781 on gallbladder carcinoma in BK5.erbB2 mice. J Hepatol. 2012; 57(1):84-91. PMC: 3378818. DOI: 10.1016/j.jhep.2012.01.018. View

18.

Ramaswamy B, Fiskus W, Cohen B, Pellegrino C, Hershman D, Chuang E . Phase I-II study of vorinostat plus paclitaxel and bevacizumab in metastatic breast cancer: evidence for vorinostat-induced tubulin acetylation and Hsp90 inhibition in vivo. Breast Cancer Res Treat. 2011; 132(3):1063-72. PMC: 3486521. DOI: 10.1007/s10549-011-1928-x. View

19.

Wang H, Cao Q, Dudek A . Phase II study of panobinostat and bortezomib in patients with pancreatic cancer progressing on gemcitabine-based therapy. Anticancer Res. 2012; 32(3):1027-31. View

20.

Miller C, Singh M, Rivera-Del Valle N, Manton C, Chandra J . Therapeutic strategies to enhance the anticancer efficacy of histone deacetylase inhibitors. J Biomed Biotechnol. 2011; 2011:514261. PMC: 3134392. DOI: 10.1155/2011/514261. View